Andreas Bergmann

B·R·A·H·M·S GmbH engages in the development and manufacture of novel diagnostic testing procedures. Its products include B·R·A·H·M·S PCT (Procalcitonin), MR-proADM (Mid-regional proadrenomedullin), Copeptin proAVP, Neopterin, and KRYPTOR Instruments. The company was founded in 1994 and is headquartered in Hennigsdorf, Germany.

in.vent DIAGNOSTICA GmbH engages in the development and production of in vitro diagnostics. It specializes in the procurement, processing and distribution of human biological materials. The firm also manufactures long-term control materials for internal quality assurance purposes which are used in medical laboratory routines. The comapny products include InQualiCheck, serum and plasma, tissue and proteins and antibodies. in.vent DIAGNOSTICA was founded in 1997 and is headquartered in Hennigsdorf, Germany.

SphingoTec GmbH develops method for prediction, prevention, intervention of cancer, cardiovascular disease and kidney function. The firm specializes in biomarker discovery and acute care diagnostics. The company was founded by Andreas Bergmann in 2002 and is headquartered in Hennigsdorf, Germany.

InVivo BioTech Services GmbH engages in contract manufacturing organization dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. The company was founded by Andreas Bergmann in 1998 and is headquartered in Hennigsdorf, Germany.

Part of Reaction Biology Corp., Bioassay Labor für biologische Analytik GmbH is a contract service organization based in Heidelberg, Germany. The German company specializes in the development and validation of bioassays for pharmaceutical potency testing, with services performed under GMP and GLP certification to meet regulatory guidance for pre-market and on-market products. The company was founded by Andreas Bergmann and the CEOs are Axel Hohenstein and Sven-Michael Cords. Bioassay Labor für biologische Analytik GmbH was acquired by Reaction Biology Corp. on December 02, 2022.

4teen4 Pharmaceuticals GmbH engages in the research and development in diagnostic and therapeutics bio markets. The company was founded by Andreas Bergmann in 2013 and is headquartered in Hennigsdorf, Germany.